Evidence map›Paper›PMID 37749143›Full record

ArticleCell death & disease2023

Identification of a miRNA multi-targeting therapeutic strategy in glioblastoma.

Arthur Bassot, Helena Dragic, Sarah Al Haddad, Laurine Moindrot, Soline Odouard, Francesca Corlazzoli, Eliana Marinari, Alexandra Bomane, Augustin Brassens, Antoine Marteyn and 16 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Pharmaceuticals (Basel, Switzerland) · 2025
    Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Human mutation · 2025
    Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 5 institutions in 3 countries.

Arthur Bassot *Department of CITI, Team GLIMMER Of lIght, Cancer Research Centre of Lyon - CRCL, INSERM U1052, CNRS UMR 5286, Lyon, France.
Helena Dragic *Department of CITI, Team GLIMMER Of lIght, Cancer Research Centre of Lyon - CRCL, INSERM U1052, CNRS UMR 5286, Lyon, France.
Sarah Al Haddad *Laboratory of Tumor Immunology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland.
Laurine MoindrotDepartment of CITI, Team GLIMMER Of lIght, Cancer Research Centre of Lyon - CRCL, INSERM U1052, CNRS UMR 5286, Lyon, France.
Soline OdouardLaboratory of Tumor Immunology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland.
Francesca CorlazzoliLaboratory of Tumor Immunology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland.
Eliana MarinariLaboratory of Tumor Immunology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland.
Alexandra BomaneDepartment of CITI, Team Cell Death and Chilhood Cancers, Cancer Research Centre of Lyon - CRCL, INSERM U1052, CNRS UMR 5286, Lyon, France.
Augustin BrassensDepartment of CITI, Team GLIMMER Of lIght, Cancer Research Centre of Lyon - CRCL, INSERM U1052, CNRS UMR 5286, Lyon, France.
Antoine MarteynLaboratory of Tumor Immunology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland.
Youssef HibaouiService de Gynécologie Obstétrique, HFR Fribourg - Hôpital Cantonal, Fribourg, Switzerland.
Tom J PettySwiss Institute of Bioinformatics, Geneva, Switzerland.
Mounira Chalabi-DcharDepartment of CITI, Team Ribosome, Translation & Cancer, Cancer Research Centre of Lyon - CRCL, INSERM U1052, CNRS UMR 5286, Lyon, France.
Louis LarrouquereDepartment of CITI, Team GLIMMER Of lIght, Cancer Research Centre of Lyon - CRCL, INSERM U1052, CNRS UMR 5286, Lyon, France.
Evgeny M ZdobnovDepartment of Genetic Medicine and Development, University of Geneva, and Swiss Institute of Bioinformatics, Geneva, Switzerland.ORCID 0000-0002-5178-1498
Noémie LegrandCenter for Translational Research in Onco-Hematology, Department of Oncology, University Hospital of Geneva, University of Geneva, Geneva, Switzerland.
Jérôme TamburiniCenter for Translational Research in Onco-Hematology, Department of Oncology, University Hospital of Geneva, University of Geneva, Geneva, Switzerland.
Hubert LincetDepartment of CITI, Team GLIMMER Of lIght, Cancer Research Centre of Lyon - CRCL, INSERM U1052, CNRS UMR 5286, Lyon, France.
Marie CastetsDepartment of CITI, Team Cell Death and Chilhood Cancers, Cancer Research Centre of Lyon - CRCL, INSERM U1052, CNRS UMR 5286, Lyon, France.ORCID 0000-0002-6758-0017
Mayra YebraDepartment of Surgery, Moores Cancer Center, University of California San Diego, La Jolla, CA, 92037, USA.
Denis MiglioriniCenter for Translational Research in Onco-Hematology, Department of Oncology, University Hospital of Geneva, University of Geneva, Geneva, Switzerland.
Valérie DutoitLaboratory of Tumor Immunology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland.
Paul R WalkerCenter for Translational Research in Onco-Hematology, Department of Oncology, University Hospital of Geneva, University of Geneva, Geneva, Switzerland.ORCID 0000-0001-8999-6366
Olivier Preynat-SeauveDepartment of Pathology and Immunology, Medical School, University of Geneva, Geneva, Switzerland.
Pierre-Yves DietrichLaboratory of Tumor Immunology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland.
Érika CossetDepartment of CITI, Team GLIMMER Of lIght, Cancer Research Centre of Lyon - CRCL, INSERM U1052, CNRS UMR 5286, Lyon, France. Erika.cosset@unige.ch.ORCID 0000-0001-5481-6556
University of Geneva · CHCentre National de la Recherche Scientifique · FRFribourg Development Agency · CHSIB Swiss Institute of Bioinformatics · CHUniversity of California San Diego · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GBM) is a deadly and the most common primary brain tumor in adults. Due to their regulation of a high number of mRNA transcripts, microRNAs (miRNAs) are key molecules in the control of biological processes and are thereby promising therapeutic targets for GBM patients. In this regard, we recently reported miRNAs as strong modulators of GBM aggressiveness. Here, using an integrative and comprehensive analysis of the TCGA database and the transcriptome of GBM biopsies, we identified three critical and clinically relevant miRNAs for GBM, miR-17-3p, miR-222, and miR-340. In addition, we showed that the combinatorial modulation of three of these miRNAs efficiently inhibited several biological processes in patient-derived GBM cells of all these three GBM subtypes (Mesenchymal, Proneural, Classical), induced cell death, and delayed tumor growth in a mouse tumor model. Finally, in a doxycycline-inducible model, we observed a significant inhibition of GBM stem cell viability and a significant delay of orthotopic tumor growth. Collectively, our results reveal, for the first time, the potential of miR-17-3p, miR-222 and miR-340 multi-targeting as a promising therapeutic strategy for GBM patients.

Indexed as

GlioblastomaMicroRNAsAdultAnimalsBiopsyCell DeathDisease Models, AnimalHumansMiceMicroRNAsMIRN340 microRNA, human

Identifiers

PMID37749143
PMCPMC10519979
OpenAlexW4387021827

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.